AstraZeneca signed a deal worth up to $1 billion to acquire Belgium-based biotech EsoBiotec and its Engineered NanoBody Lentiviral platform, which uses lentiviruses to deliver genetic instructions to ...

All cells were cultured in 95% air and 5% CO 2 at 37°C. The LRP1B-RNAi and negative control lentiviruses were purchased from Shanghai Jikai Company (Shanghai, China). The cells were infected with ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...

That therapy, like others EsoBiotech is developing, uses what it calls novel, “highly targeted” lentiviruses to deliver genetic instructions into immune cells. This reprogramming process is done ...